Integra Lifesciences Holdings Corp

This non-binding advisory proposal asks stockholders to approve the Company’s 2025 named executive officer (NEO) compensation as described in the proxy statement, including the Compensation Discussion and Analysis and related tables and narrative. Management seeks this advisory vote to confirm stockholder support for its pay-for-performance philosophy, which emphasizes a majority of at‑risk compensation through a mix of annual cash incentives and long‑term equity awards (PSUs, RSUs/RSAs and, historically, options). The Board and Compensation Committee argue that the program aligns executive incentives with long‑term shareholder value by tying short‑term bonuses to revenue, adjusted EBITDA and operating cash flow, and PSUs to multi‑year organic revenue growth (with changes planned to add adjusted EBITDA margin beginning in 2026). The proxy also discloses that, after consideration of 2025 results, the Compensation Committee exercised discretion (including a tariff adjustment and supplemental discretionary funding) when setting the 2025 bonus pool, and that PSUs vested at 0% for the 2025 performance year given organic growth results. The filing highlights strong prior stockholder support (98.1% approval in 2025) and ongoing engagement with investors representing roughly 40% of outstanding shares, which the Committee cites as validation of its approach. Key governance features—such as clawback policies, stock ownership guidelines, no hedging/pledging, double‑trigger change‑in‑control protections, and independent consultant review—are used to support the Board’s recommendation. Voting in favor is intended to signal continued stockholder endorsement of the program design; however, the advisory nature means the Board will consider the vote results and investor feedback in future compensation decisions rather than being strictly bound by the outcome. Investors analyzing this proposal should weigh the tension between discretionary adjustments (tariff and bonus discretion) and the program’s structural alignment mechanisms, and consider historical Say‑on‑Pay support and recent operational context (quality and supply challenges, transformation plans) when assessing management’s rationale.

This proposal requests shareholder approval to increase the authorized share reserve under Integra’s 2003 Equity Incentive Plan by 3,550,000 shares, bringing the Plan’s total share limit to 24,250,000 if approved. Management and the Compensation Committee contend the expansion is required to continue granting equity awards consistent with historical practice and to remain competitive for talent; they project the additional shares will provide roughly a two‑year runway based on historical run rates (2025 run rate ~2.52%, three‑year average ~1.72%). The filing explains that as of March 13, 2026 only ~1.46 million shares remained available, and without an increase equity grants could be constrained, forcing greater reliance on cash compensation or other alternatives that may misalign employee and shareholder incentives. The Committee considered dilution and overhang — disclosing outstanding awards, weighted‑average exercise price, and estimating that the amendment would increase overhang by ~4.71%, to a total overhang of ~14.35% — and engaged an independent compensation consultant in its analysis. The Plan contains anti‑dilution and adjustment provisions and limits on annual awards to any single employee, and the Board highlights that the Plan does not have an evergreen provision; shareholder approval is therefore required for this one‑time increase. In recommending a FOR vote, the Board balanced the need to preserve equity‑based compensation as a key retention and alignment tool against dilutive impacts, concluding the requested reserve is reasonable given hiring, retention, and strategic plan needs. Sophisticated evaluators should consider the Company’s historical grant practices, equity mix (full‑value awards vs. options), the Company’s share run rate trajectory, recent operational performance and PSU payout history, and potential future dilution when assessing whether the proposed increase is in stockholders’ long‑term interests.